Get to know our Partner, Paul Hemings. Decades across investment banking, healthcare, and boardrooms distilled into five rules he never breaks. ● Know the founder - deeply. Never invest without clarity on the person, their motivations, pressures, and cap table realities. ● Follow the incentives. Alignment on governance, economics, and decision rights - or expect drift. ● Plan the exit early. Map options (strategic, sponsor-to-sponsor, IPO) and build toward them from day one. ● Respect execution risk. As a 2× founder, he’s seen how operational complexity compounds fast - plan accordingly. ● Never compromise on trust. Character, transparency, and follow-through are non-negotiable.

From Medicine to the Boardroom: 3 lessons from our Partner Nadiia Wyttenbach. • The Quantum Physicist Exercise: your prior experience ≠ the target or new industry. With ~90% of deals in adjacencies, treat each like “new physics” - assume less, listen & measure more. That’s how you beat confirmation bias. • There’s always a second patient: visible symptoms (e.g., weak finance functions) often stem from board gaps, owner dynamics, or generational friction. Find the second patient to unlock durable performance. • Bring cognitive psychology to boardrooms and M&A: know yourself, know others, know the terrain. In that order. Surface unmet needs early - or they’ll steer your decisions (and valuations) from the shadows.

• Two lenses, one story: Paul shares the lived reality of access, reimbursement, and day-to-day life for two family members with Type 1 diabetes. Nadiia explains why she dedicated her PhD to obesity & Type 2 diabetes - and what’s changed since. • Why Nadiia chose obesity: long before it was mainstream, she saw obesity as a molecular health disorder, not a willpower issue - sitting at the intersection of biology, human cost, and an empathy gap. • From stigma to solutions: healthcare professionals working for decades across R&D, injectable devices, manufacturing, payers, regulators - and yes, capital markets - laid the groundwork for today’s therapies (GLP-1 receptor agonists like semaglutide, duals like tirzepatide, next-gen combos). Not every program survived, but progress compounded. And together, look how far we have come. Watch the clip below.